435 related articles for article (PubMed ID: 28615036)
1. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
3. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
4. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
5. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
6. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
Vojinović J; Foeldvari I; Dehoorne J; Panaviene V; Susic G; Horneff G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Akikusa J; Avcin T; Borlenghi C; Arthur E; Tatulych SY; Zang C; Tsekouras V; Vlahos B; Martini A; Ruperto N
Rheumatology (Oxford); 2024 Jan; 63(1):140-148. PubMed ID: 37140539
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
9. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
10. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
[TBL] [Abstract][Full Text] [Related]
11. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept.
Klotsche J; Minden K; Thon A; Ganser G; Urban A; Horneff G
Arthritis Care Res (Hoboken); 2014 Feb; 66(2):253-62. PubMed ID: 23983081
[TBL] [Abstract][Full Text] [Related]
12. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.
Anink J; Van Suijlekom-Smit LW; Otten MH; Prince FH; van Rossum MA; Dolman KM; Hoppenreijs EP; ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Vogl T; Gohar F; Foell D; Roth J; Holzinger D
Arthritis Res Ther; 2015 Aug; 17(1):200. PubMed ID: 26249667
[TBL] [Abstract][Full Text] [Related]
13. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis.
Geikowski T; Becker I; Horneff G;
Rheumatology (Oxford); 2014 Jul; 53(7):1245-9. PubMed ID: 24599916
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
16. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
[TBL] [Abstract][Full Text] [Related]
17. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
19. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
[TBL] [Abstract][Full Text] [Related]
20. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
